<DOC>
	<DOCNO>NCT00372528</DOCNO>
	<brief_summary>The main purpose trial allow continue access pregabalin Canadian subject participate global pregabalin epilepsy study 1008-010 ; 1008-035 ; 1008-114 1008-164 continue study long term safety pregabalin administer adjunctive therapy dosages 150 mg/day 600 mg/day Canadian subject refractory partial seizure .</brief_summary>
	<brief_title>An Open-Label Study Of Pregabalin In Subjects With Refractory Partial Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Must complete Pfizer openlabel study 1008010 ; 1008035 ; 1008114 1008164 wish continue receive openlabel pregabalin Must respond favorably pregabalin Pfizer openlabel study 1008010 , 1008035 , 1008114 1008164 clinical opinion investigator continue treatment pregabalin patient 's best medical interest Is pregnant consider become pregnant course study Experienced serious adverse event openlabel Pfizer study 1008010 , 1008035 , 1008114 1008164</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>